Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal discontinuation timing of fospropofol disodium for maintenance of general anesthesia
ChiCTR2500111911Phase 4Not yet recruiting
- Sponsor
- Tai'an City Central Hospital
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of fospropofol disodium in pulmonary diseases and bronchial carcinoma (4 arms), sponsored by Tai'an City Central Hospital. Primary endpoint: Time from the end of surgery to patient emergence. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
fospropofol disodium
03
Conditions
pulmonary diseasesbronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500111911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111911.